Log in

Can-Fite BioPharma Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average Volume293,343 shs
Market Capitalization$28.59 million
P/E RatioN/A
Dividend YieldN/A
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.13 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Phone972 3 924 1114



Sales & Book Value

Annual Sales$2.03 million
Book Value$0.66 per share


Net Income$-9,590,000.00
Net Margins-781.44%


Market Cap$28.59 million
Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive CANF News and Ratings via Email

Sign-up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Can-Fite BioPharma (ARCA:CANF) Frequently Asked Questions

What stocks does MarketBeat like better than Can-Fite BioPharma?

Wall Street analysts have given Can-Fite BioPharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Can-Fite BioPharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Can-Fite BioPharma's key competitors?

Who are Can-Fite BioPharma's key executives?

Can-Fite BioPharma's management team includes the following people:
  • Dr. Pnina Fishman, Scientific Founder, CEO & Director (Age 72, Pay $379k)
  • Mr. Motti Farbstein, Chief Operating & Financial Officer (Age 56, Pay $210k)
  • Dr. Sari Fishman Ph.D., VP of Bus. Devel. (Age 48, Pay $161k)
  • Dr. Ilan Cohn, Co-Founder & Chairman (Age 66)
  • Dr. Vibeke Strand FACR, M.D., FACP, FACR (USA), Sr. Clinical Advisor

What is Can-Fite BioPharma's stock symbol?

Can-Fite BioPharma trades on the ARCA under the ticker symbol "CANF."

How do I buy shares of Can-Fite BioPharma?

Shares of CANF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Can-Fite BioPharma?

Can-Fite BioPharma has a market capitalization of $0.00 and generates $2.03 million in revenue each year. The company earns $-9,590,000.00 in net income (profit) each year or ($3.30) on an earnings per share basis. Can-Fite BioPharma employs 8 workers across the globe.

What is Can-Fite BioPharma's official website?

The official website for Can-Fite BioPharma is www.canfite.com.

How can I contact Can-Fite BioPharma?

Can-Fite BioPharma's mailing address is 10 BAREKET STREET KIRYAT MATALON P.O. BOX 7537, PETACH TIKVA L3, 4951778. The company can be reached via phone at 972 3 924 1114 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.